Combination Therapy Shows Promise in Glioblastoma

by: cancercompass

Combining radiotherapy, lomustine (CCNU), and temozolomide (TMZ) showed promising results for long-term survival in patients newly diagnosed with glioblastoma, according to a study published this month in the Journal of Clinical Oncology.

Researchers analyzed 39 patients receiving radiotherapy solely at the tumor site and a combination of CCNU and TMZ chemotherapy. Eight of those 39 received an intensified dosage of CCNU and TMZ chemotherapy.

Overall findings were a median survival of 23.1 months. Of the patients 47.4% survived for two years, while 18.5% survived for four years. The intensified group showed a median survival of 41.5 months, however the intensified CCNU/TMZ dosage may add a greater acute toxicity.  

Brain cancer treatment options vary depending on the type of tumor.  Join our brain cancer discussion board to connect with other patients, survivors and caregivers.